These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 19674731

  • 1. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
    Ahn JK, Moon HJ.
    Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C, Semeraro F, dell'Omo R, Romano MR, Russo A, Aceto F, Mastropasqua R, Porcellini A.
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [Abstract] [Full Text] [Related]

  • 3. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 4. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group.
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [Abstract] [Full Text] [Related]

  • 5. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
    Wang JW, Zhou MW, Zhang X, Huang WB, Gao XB, Wang W, Chen S, Zhang XY, Ding XY, Jonas JB.
    Clin Exp Ophthalmol; 2015 Jul; 43(5):415-21. PubMed ID: 25488632
    [Abstract] [Full Text] [Related]

  • 6. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.
    Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Lüke M, Bartz-Schmidt KU, Grisanti S.
    Am J Ophthalmol; 2006 Jul; 142(1):95-104. PubMed ID: 16815256
    [Abstract] [Full Text] [Related]

  • 7. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
    Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS.
    Am J Ophthalmol; 2006 Mar; 141(3):456-62. PubMed ID: 16490490
    [Abstract] [Full Text] [Related]

  • 8. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 Mar; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

  • 9. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R, Gabric N.
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.
    Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW.
    Arch Ophthalmol; 2005 Apr; 123(4):509-16. PubMed ID: 15824225
    [Abstract] [Full Text] [Related]

  • 11. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA.
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [Abstract] [Full Text] [Related]

  • 12. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR.
    Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
    [Abstract] [Full Text] [Related]

  • 13. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L, Leys A.
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [Abstract] [Full Text] [Related]

  • 14. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
    Cho M, Barbazetto IA, Freund KB.
    Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
    [Abstract] [Full Text] [Related]

  • 15. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A, DENALI Study Group.
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [Abstract] [Full Text] [Related]

  • 16. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 17. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group.
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [Abstract] [Full Text] [Related]

  • 18. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
    Park SP, Ahn JK.
    Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
    [Abstract] [Full Text] [Related]

  • 19. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A, MONT BLANC Study Group.
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [Abstract] [Full Text] [Related]

  • 20. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.